DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.
Saved in:
| Title: | DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. |
|---|---|
| Authors: | Momeny M; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. majid.momeny@uth.tmc.edu.; The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA. majid.momeny@uth.tmc.edu., Tienhaara M; Medicity Research Laboratories, Faculty of Medicine, University of Turku, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland., Sharma M; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland., Chakroborty D; Medicity Research Laboratories, Faculty of Medicine, University of Turku, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland., Varjus R; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Takala I; Medicity Research Laboratories, Faculty of Medicine, University of Turku, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland., Merisaari J; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Padzik A; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Vogt A; University of Pittsburgh Drug Discovery Institute, Department of Computational and Systems Biology, Pittsburgh Technology Center, Pittsburgh, PA, USA., Paatero I; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Elenius K; Medicity Research Laboratories, Faculty of Medicine, University of Turku, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland., Laajala TD; Department of Mathematics and Statistics, University of Turku, Turku, Finland., Kurppa KJ; Medicity Research Laboratories, Faculty of Medicine, University of Turku, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland., Westermarck J; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. jukwes@utu.fi.; Institute of Biomedicine, University of Turku, Turku, Finland. jukwes@utu.fi. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2024 Jul; Vol. 16 (7), pp. 1603-1629. Date of Electronic Publication: 2024 Jun 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
